PeproMene Bio’s EHA 2026 data spotlight BAFF-R CAR T in relapsed lymphoma
PeproMene Bio’s PMB-CT01 data raise fresh questions for post-CD19 CAR T lymphoma care. Find out what the early signal means.
Pharma & Biotech
Pharma & Biotech
Can mitochondrial stress be weaponized in cancer? Bantam starts BTM-3566 dosing
Bantam Pharmaceutical has treated the first patient with BTM-3566 in a Phase 1 clinical trial at the Princess Margaret Cancer Centre in Toronto. The study marks the first-in-human administration of the company’s lead investigational therapy, a first-in-class small molecule designed to treat aggressive cancers by modulating the OMA1-ATF4 integrated stress response pathway. This trial includes